文献詳細
増刊号 最新臨床研究から探る眼科臨床のギモンQ&A
5 網膜硝子体
文献概要
抗VEGF薬を単回投与し,その後は,活動性の持続もしくは再燃が確認された場合に再投与を行うpro re nata (PRN)方式をとります.
参考文献
1)Wolf S et al;RADIANCE Study Group:RADIANCE:a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 121:682-692.e2, 2014
2)Ikuno Y et al:Intravitreal aflibercept injection in patients with myopic choroidal neovascularization:The MYRROR Study. Ophthalmology 122:1220-1227, 2015
3)Yoshida T et al:Myopic choroidal neovascularization:a 10-year follow-up. Ophthalmology 110:1297-1305, 2003
4)Tan NW et al:Long-term outcomes of ranibizumab treatment of myopic choroidal neovascularization in east-asian patients from the RADIANCE study. Retina 38:2228-2238, 2018
5)Oishi A et al:Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 251:1-7, 2013
6)Kasahara K et al:Six-year outcomes of intravitreal bevacizumab for choroidal neovascularization in patients with pathologic myopia. Retina 37:1055-1064, 2017
7)Onishi Y et al:Five-year outcomes of intravitreal ranibizumab for choroidal neovascularization in patients with pathologic myopia. Retina 39:1289-1298, 2019
8)Ohno-Matsui K et al:Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia. Prog Retin Eye Res 63:92-106, 2018
掲載誌情報